Zacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) Will Announce Earnings of -$0.05 Per Share

Analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce earnings per share (EPS) of ($0.05) for the current quarter, Zacks reports. Zero analysts have made estimates for AVEO Pharmaceuticals’ earnings. AVEO Pharmaceuticals reported earnings of ($0.07) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The firm is scheduled to announce its next quarterly earnings results on Friday, November 3rd.

According to Zacks, analysts expect that AVEO Pharmaceuticals will report full-year earnings of ($0.55) per share for the current fiscal year. For the next year, analysts forecast that the company will post earnings of ($0.36) per share. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow AVEO Pharmaceuticals.

Several analysts have issued reports on AVEO shares. ValuEngine lowered shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $3.50 price target on shares of AVEO Pharmaceuticals in a research report on Thursday, August 10th. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Monday, July 24th. FBR & Co reaffirmed an “outperform” rating and set a $3.00 price target on shares of AVEO Pharmaceuticals in a research report on Thursday, July 13th. Finally, BidaskClub raised shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $3.42.

AVEO Pharmaceuticals (NASDAQ AVEO) traded down 3.10% on Monday, reaching $3.60. 2,535,170 shares of the company were exchanged. The stock has a 50 day moving average of $3.26 and a 200 day moving average of $1.68. AVEO Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $4.24. The firm’s market capitalization is $425.91 million.

COPYRIGHT VIOLATION WARNING: This story was published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://sportsperspectives.com/2017/09/23/zacks-brokerages-anticipate-aveo-pharmaceuticals-inc-aveo-will-announce-earnings-of-0-05-per-share.html.

Large investors have recently added to or reduced their stakes in the business. Fore Research & Management LP acquired a new position in shares of AVEO Pharmaceuticals in the second quarter valued at $111,000. Clear Harbor Asset Management LLC acquired a new position in shares of AVEO Pharmaceuticals in the second quarter valued at $289,000. Cannell Peter B & Co. Inc. increased its holdings in shares of AVEO Pharmaceuticals by 22.9% in the second quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 20,500 shares during the last quarter. Paloma Partners Management Co acquired a new position in shares of AVEO Pharmaceuticals in the first quarter valued at $184,000. Finally, UBS Oconnor LLC acquired a new position in shares of AVEO Pharmaceuticals in the first quarter valued at $291,000. Hedge funds and other institutional investors own 53.76% of the company’s stock.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply